Human Papillomavirus Genotypes in Cervical Intraepithelial Neoplasia Grade 3
- 1 July 2010
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 19 (7) , 1675-1681
- https://doi.org/10.1158/1055-9965.epi-10-0251
Abstract
Background: There are few large case series describing the human papillomavirus (HPV) genotypes found in women diagnosed with rigorously reviewed cervical intraepithelial neoplasia grade 3 (CIN3), cervical precancer. Methods: The Atypical Squamous Cells of Undetermined Significance (ASCUS) and Low-Grade Squamous Intraepithelial Lesion (LSIL) Triage Study (ALTS) was a clinical trial to evaluate the best management strategies for women with equivocal (ASCUS) or mildly abnormal (LSIL) Pap tests. During enrollment and the 2-year follow-up, 608 women had a histopathologic diagnosis of CIN3 and PCR-based HPV genotyping results on cervical specimens. The genotyping results were ranked hierarchically according to cancer risk: HPV16 > other carcinogenic HPV > noncarcinogenic HPV > PCR negative. Results: Among the 608 women diagnosed with CIN3, 601 (98.8%) cases were positive for any HPV genotype and 95.4% for any carcinogenic HPV. HPV16 (59.9%), HPV31 (18.1%), HPV52 (14.8%), HPV51 (14.0%), and HPV18 (13.2%) were the five most common HPV genotypes detected. Younger age, consensus histologic confirmation, smoking, and multiparity increased the likelihood of testing HPV 16 positive. Specifically, HPV16-positive CIN3 occurred at a younger age than CIN3 positive for other carcinogenic HPV genotypes (median of 23.5 years versus 25 years, respectively; P = 0.0003, Kruskal-Wallis). Conclusions: HPV16-positive CIN3 was more commonly diagnosed in younger women (versus older women), with consensus diagnosis (versus some disagreement between reviewers), and in smokers (versus nonsmokers), and was less commonly diagnosed in multiparous women compared CIN3 positive for other carcinogenic HPV genotypes. Impact: In populations vaccinated against HPV16 (and HPV18), the median age of CIN3 in women with ASCUS and LSIL cytology should shift to older ages, possibly permitting later age at first screening. Cancer Epidemiol Biomarkers Prev; 19(7); 1675–81. ©2010 AACR.This publication has 35 references indexed in Scilit:
- Impact of Improved Classification on the Association of Human Papillomavirus With Cervical PrecancerAmerican Journal of Epidemiology, 2009
- Age-appropriate use of human papillomavirus vaccines in the U.S.Gynecologic Oncology, 2009
- Detection of Precancerous Cervical Lesions Is Differential by Human Papillomavirus TypeCancer Research, 2009
- Human Papillomavirus Genotype Distributions: Implications for Vaccination and Cancer Screening in the United StatesJNCI Journal of the National Cancer Institute, 2009
- A review of human carcinogens—Part B: biological agentsThe Lancet Oncology, 2009
- Human Papillomavirus Types by Age in Cervical Cancer Precursors: Predominance of Human Papillomavirus 16 in Young WomenCancer Epidemiology, Biomarkers & Prevention, 2009
- Factors Influencing Histologic Confirmation of High-Grade Squamous Intraepithelial Lesion CytologyObstetrics & Gynecology, 2008
- A Comparison of Linear Array and Hybrid Capture 2 for Detection of Carcinogenic Human Papillomavirus and Cervical Precancer in ASCUS-LSIL Triage StudyCancer Epidemiology, Biomarkers & Prevention, 2008
- Human papillomavirus type distribution in invasive cervical cancer and high‐grade cervical lesions: A meta‐analysis updateInternational Journal of Cancer, 2007
- Human Papillomavirus Type 16 Infections and 2-Year Absolute Risk of Cervical Precancer in Women With Equivocal or Mild Cytologic AbnormalitiesJNCI Journal of the National Cancer Institute, 2005